10-17-2001

FORM F O-1595 (Modified)

Name of Person Signing

Docket No.: 00-331-B

U.S. DEPARTMENT OF COMMERCE

(Rev. 6-9-2 OMB No. 0651-0011 (exp.4/94) Copyright 1994-97 LegalStar	Patent and Trademark Office				
POB/REV02 Tab settings → → → ▼ 1,01876	6208 ▼ ▼ ▼				
	: Please record the attached original documents or copy thereof.				
1. Name of conveying party(ies): Mark H. Norman	2. Name and address of receiving party(ies):				
10-10	Name: Amgen Inc.				
	Internal Address:				
Additional names(s) of conveying party(ies)					
3. Nature of conveyance:					
☑ Assignment ☐ Merger	Street Address: One Amgen Center Drive				
☐ Security Agreement ☐ Change of Name					
☐ Other	City: Thousand Oaks State: CA ZIP: 91320				
Execution Date: September 26, 2001	Additional name(s) & address(es) attached? Yes No				
4. Application number(s) or registration numbers(s):					
If this document is being filed together with a new application	n, the execution date of the application is:				
A. Patent Application No.(s) B. Patent No.(s)					
09/899,654					
Additional numbers atta 5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved:				
Name: Stephen H. Docter	7. Total fee (37 CFR 3.41):\$ 40.00				
Internal Address: McDonnell Boehnen Hulbert	Enclosed - Any excess or insufficiency should be credited or debited to deposit account				
& Berghoff	☐ Authorized to be charged to deposit account				
Street Address: 300 South Wacker Drive, Suite 3200	8. Deposit account number:				
	13-2490				
City: Chicago State: IL ZIP: 60606					
0/16/2001 DBYRNE 00000049 09899654 DO NO	OT USE THIS SPACE				
40.00 CP					
9. Statement and signature. To the best of my knowledge and belief, the foregoing information of the principal document.	rmation is true and correct and any attached copy is a true copy				
of the original document. Stephen H. Docter	when A. All October 5, 2001				
Name of Porcon Signing	Signature Date				

Total number of pages including cover sheet, attachments, and document:

PATENT

REEL: 012242 FRAME: 0348

Docket No.: 00-331-B

ASSIGNMENT

Whereas	s, we, Laurence E. Burgess 5562 High Country Court, Boulder, Colorado 80301				
	John J. Gaudino 4224 Prairie Fire Circle, Longmont, Colorado 80503				
· · · · · · · · · · · · · · · · · · ·	Robert D. Groneberg 958 Yellow Pine Avenue, Boulder, Colorado 80304				
-	Mark H. Norman 130 Venus Street, Thousand Oaks, California 91360				
	Martha A. Rodriguez 3549 Larkspur Drive, Longmont, Colorado 80503				
	Xicheng Sun 923 Grays Peak Drive, Superior, Colorado 80027				
	Eli M. Wallace P.O.Box 1727, Lyons, Colorado 80540				
entitled	ntion which is the subject of an application for Letters Patent of the United States ("Application") RATION OF PHOSPHATASE INHIBITORS				
THEFA	ATION OF THOSE NATIONAL INVIDENCE				
which is found in:					
☐ (a)	JS Patent Application executed on even date herewith;				
(b)	the US Patent Application executed on				
	US Application Serial No.: 09/899,654 filed on July 5, 2001				
☐ (d)	US Patent No.:				

Whereas AMGEN INC., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, wishes to acquire the entire interest in all inventions disclosed in such Application:

Now, therefore, in consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto AMGEN INC., its successors and assigns (collectively "AMGEN") our entire right, title and interest in, to and under the Application, and any provisional application(s) from which Application is derived, and all priority rights to which the Application may be entitled, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and of all other countries which may be granted for such inventions, or any of them, including divisional, continuation, and/or continuation-in-part applications based on the above-identified Application, all such inventions and all rights in such Application and Letters Patent to be held and enjoyed by AMGEN for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by us had this assignment and sale not been made.

Further, we hereby sell, assign, transfer, and set over unto AMGEN our entire right, title and interest in or to the right to refer to, to access, and to control microorganism(s) or other biological material(s) related to the Application and which are deposited by us or at our direction or deposited on our behalf by Amgen, its affiliates, employees or employees of its affiliates. The transfer of such right, title and interest includes, without limitation, our unreserved and irrevocable consent and authorization to AMGEN to refer to the deposited microorganisms(s) or other biological materials(s) in the Application and the right to make available to the public the deposited material in accordance with the laws, treaties, statutes, rules, regulations and the like of the United States, all other countries, and any patent granting authority or organization.

We authorize and request the Commissioner of Patents and Trademarks of the United States to issue any such Letters Patent which may be granted on the Application to AMGEN as assignee of the entire right, title and interest therein and thereto.

1

PATENT REEL: 012242 FRAME: 0349

Docket No.: 00-331-B

For ourselves and for our legal representatives, we covenant and agree with AMGEN that we have not granted to any others any license to make, use or sell any of such inventions, that our right title and interest in such inventions has not been encumbered, that we have good right and title to sell and assign the same, and that we will not execute any instrument in conflict herewith.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with AMGEN that upon request we and they will: (i) execute continuing, divisional or reissue applications, amended specifications, or rightful declarations or oaths; (ii) communicate to AMGEN any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings or litigations; (iv) execute and deliver any application papers, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for AMGEN, may be necessary or desirable to secure the grant of Letters Patent to AMGEN or its nominees, in the United States and in all other countries where AMGEN may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for AMGEN and to vest and confirm in AMGEN or its nominees, the full and complete legal and equitable title to all such Letters Patent, without further consideration than that now paid but at the expense of AMGEN.

In Witness Whereof I have execute	d this assignment on the	26th day of	September	20 <u>01</u>
Mark H. Norman (Name of Inventor)		(Sign	ature of Inventor)	
ı	UNITED STATES OF AME	ERICA		
State of California County of Ventura ss:		September	36	20 <u>01</u>
Before me, a Notary Public for Ven	tura County, State of Califo	ornia, personally	appeared _	
Mark H. Morm	ax)			
personally known to me - OR -		e within instrume me in his/ her a instrument the p	uthorized capacity erson, or the entit	, and that by
	WITNESS my hand and o	official seal.	1. Lutterse)
			mission expires	
CHRISTINA A. GUTIERREZ Commission # 1200954 Notary Public — California Ventura County My Comm. Expires Nov 4, 2000	NAME OF THE PROPERTY OF THE PR	Jovember	6	<20 <u>0</u> 2

RECORDED: 10/10/2001

PATENT REEL: 012242 FRAME: 0350